Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$77.25

-1.46 (-1.85%)

09:58
04/25/19
04/25
09:58
04/25/19
09:58

AbbVie says 'feels very good' about progress with gross margin

Says: Sees FY adjusted gross margin approaching 83%... Skyrizi has multi-billion dollar peak potential... Expects Skyrizi to ramp in very significant way... Pretty comfortable with how biosimilars are sorting themselves out... Comfortable with Humira erosion.

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

ABBV AbbVie
$77.25

-1.46 (-1.85%)

03/25/19
ARGS
03/25/19
DOWNGRADE
ARGS
Hold
AbbVie downgraded to Hold from Buy at Argus
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.

TODAY'S FREE FLY STORIES

STIM

Neuronetics

$11.41

-0.11 (-0.95%)

05:21
06/18/19
06/18
05:21
06/18/19
05:21
Recommendations
Neuronetics analyst commentary  »

Neuronetics reiterated as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

, LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

05:17
06/18/19
06/18
05:17
06/18/19
05:17
Recommendations
Lionsgate, Use LGF.A, LGF.B analyst commentary  »

Lionsgate price target…

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRAY

ViewRay

$8.96

0.215 (2.46%)

05:14
06/18/19
06/18
05:14
06/18/19
05:14
Initiation
ViewRay initiated  »

ViewRay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:12
06/18/19
06/18
05:12
06/18/19
05:12
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:11
06/18/19
06/18
05:11
06/18/19
05:11
Downgrade
Evraz rating change  »

Evraz downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:10
06/18/19
06/18
05:10
06/18/19
05:10
Downgrade
Evraz rating change  »

Evraz downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.15

0.375 (0.86%)

05:09
06/18/19
06/18
05:09
06/18/19
05:09
Upgrade
U.S. Cellular rating change  »

U.S. Cellular upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$29.21

-0.11 (-0.38%)

05:08
06/18/19
06/18
05:08
06/18/19
05:08
Upgrade
Telephone and Data rating change  »

Telephone and Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESS

Essex Property Trust

$302.21

3.03 (1.01%)

05:07
06/18/19
06/18
05:07
06/18/19
05:07
Downgrade
Essex Property Trust rating change  »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

CFPZF

Canfor

$0.00

(0.00%)

05:06
06/18/19
06/18
05:06
06/18/19
05:06
Upgrade
Canfor rating change  »

Canfor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFTBF

West Fraser Timber

$0.00

(0.00%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
West Fraser Timber rating change  »

West Fraser Timber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RFP

Resolute Forest

$6.12

0.015 (0.25%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
Resolute Forest rating change  »

Resolute Forest upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:03
06/18/19
06/18
05:03
06/18/19
05:03
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACCYY

Accor

$0.00

(0.00%)

05:02
06/18/19
06/18
05:02
06/18/19
05:02
Upgrade
Accor rating change  »

Accor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$42.65

0.19 (0.45%)

05:01
06/18/19
06/18
05:01
06/18/19
05:01
Downgrade
Sanofi rating change  »

Sanofi downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

AXELF

Axel Springer

$0.00

(0.00%)

04:59
06/18/19
06/18
04:59
06/18/19
04:59
Downgrade
Axel Springer rating change  »

Axel Springer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTSKY

Otsuka

$0.00

(0.00%)

04:58
06/18/19
06/18
04:58
06/18/19
04:58
Downgrade
Otsuka rating change  »

Otsuka downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$53.01

-0.54 (-1.01%)

04:56
06/18/19
06/18
04:56
06/18/19
04:56
Downgrade
Lennar rating change  »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

KBH

KB Home

$26.21

-0.24 (-0.91%)

04:56
06/18/19
06/18
04:56
06/18/19
04:56
Downgrade
KB Home rating change  »

KB Home downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

VZ

Verizon

$57.63

-0.65 (-1.12%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Verizon to host sell side analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

CVS

CVS Health

$54.52

0.34 (0.63%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
CVS Health participates in a conference call with JPMorgan »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

ARWR

Arrowhead

$26.43

0.62 (2.40%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Arrowhead management to meet with Piper Jaffray »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

HRB

H&R Block

$28.34

-0.35 (-1.22%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
H&R Block management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 16

    Jul

GIII

G-III Apparel

$25.67

-0.03 (-0.12%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
G-III Apparel management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

DEI

Douglas Emmett

$41.86

0.595 (1.44%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Douglas Emmett management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.